Review of botulinum toxin type A and its clinical applications in migraine headache

Bibliography

• STEWART WF, LIPTON RB, CELENTANO DD, REED ML: Prevalence of migraine in the United States. JAMA (1992)267:64–69.
   PubMed Web of Science ®Google Scholar
• CADY RK: Diagnosis and treatment of migraine. Clinical Cornerstone (1999) 1:21–32.
   PubMedGoogle Scholar
• LIPTON RB, GOADSBY P J, SILBERSTEIN SD: Classification and epidemiology of headache. Clinical Cornerstone. (1999) 1:1–10.
   PubMedGoogle Scholar
• HU HX, MARKSON LE, LIPTON RB, STEWART WF, BERGER MC: Burden of migraine in the United States. Arch. Intern. Med. (1999) 159:813–818.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ: Advances in pharmacotherapy of migraine. Drugs R&D (1999) 2:361–374.
   PubMedGoogle Scholar
• DELEU D, HANSSENS Y, WORTHINGEA: Symptomatic and prophylactic treatment of migraine: A critical reappraisal. Neuropharm. (1998) 21:267–279.
   Google Scholar
• WEILLER C, MAY A, LIMMROTH V etal.: Brain stem activation in spontaneous human migraine attacks. Nat. Med. (1995) 1:658–660.
   Google Scholar
• SANCHEZ DEL RIO M, SILBERSTEIN S D: How to pick optimal acute treatment for migraine headache. Current Pain and Headache Reports (2001) 5:170–178.
   PubMedGoogle Scholar
• SILBERSTEIN SD: Practice parameter: Evidence-based guidelines for migraine headache. Neurology (2000) 55:754–763.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, STEWART WF, SAWYER J: Stratified care is a more effective migraine treatment strategy than stepped care: results of a randomised clinical trial. Neurology (2000) 54:A14.
   Google Scholar
• LIPTON RB, STEWART WF, SIMON D: Medical consultation for migraine: results from the American migraine Study. Headache (1998)38:7–96.
   Google Scholar
• MAHANT N, CLOUSTON PD, LORENTZ IT: The current use of botulinum toxin. J. Clin. Neuroscience (2000) 7:389–394.
   Google Scholar
• BRIN MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle & Nerve (1997) 20\(Supp1.6):S146–S168.
   Google Scholar
• KRACK P, HORNIG C, DORNDORF W:Resolution of chronic tension headache after botulinum toxin treatment of idiopathic blepharospasm. Mov. Dis. (1995) 10:388.
   Google Scholar
• RELJA M: Treatment of tension-type headache by local injection of botulinum toxin. Eur. j Neuro. (1997) 4\(Suppl. 2):S71–573.
   Google Scholar
• WHEELER AH: Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache (1998) 38:468–471.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS A, LAN GTRY JA, CARRUTHERS J, ROBINSON G: Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache (1999) 39:662–665.
   PubMedGoogle Scholar
• SCHULTE-MATTLER WJ, WIESER T, ZIERZ S: Treatment of tension-type headache with botulinum toxin: a pilot study. Eur. J. Med. Res. (1999) 4:183–186.
   PubMedGoogle Scholar
• SMUTS JA, BAKER MK, SMUTS M, STASSEN JMR, ROSSOUW E, BARNARD PWA: Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur. j Neuro. (1999) 6\(Suppl. 4):599–5102.
   Google Scholar
• RELJA M: Treatment of tension-type headache with botulinum toxin: 1-year follow-up. Cephalagia (2000) 20:336.
   Google Scholar
• WOLLINA U: Botulinum A toxin for wrinkles: release from tension headache. European Acad. Berm. Venereology (2000) 14:142.
   PubMedGoogle Scholar
• HOBSON DE, GLADISH DF: Botulinum toxin injections for cervicogenic headache. Headache (1997) 37:253–255.
   PubMed Web of Science ®Google Scholar
• FREUND BJ, SCHWARTZ M: Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache (2000) 40:231–236.
   PubMed Web of Science ®Google Scholar
• SMUTS JA, BARNARD PWA: Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalagia (2000) 20:332.
   Google Scholar
• BINDER WJ, BRIN MF, BLITZER A, SCHOENROCK LD, POGODA JM: Botulinum toxin type A (BOTOX) for the treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg. (2000) 123:669–676.
   PubMed Web of Science ®Google Scholar
• BRIN MF, SWOPE DM, O'BRIEN C, ABBASI S, POGODA JM: Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalagia (2000) 20:421–422.
   Google Scholar
• MAUSKOP A, BASDEO R: Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalagia (2000) 20:422.
   Google Scholar
• SILBERSTEIN S D, MATHEW N, SAPER J, JENKINS S: Botulinum toxin type A as a migraine preventive treatment. Headache (2000) 40:445–450.
   PubMedGoogle Scholar
• HUMEAU Y, DOUSSAU F, GRANT NJ, POULAIN B: How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie (2000) 82:427–446.
   PubMed Web of Science ®Google Scholar
• BRIN MF, FAHN S, MOSKOWITZ C et al.: Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord (1987) 2:237–254.
   PubMed Web of Science ®Google Scholar
• PRIORI A, BERARDELLI A, MERCURI B, MANFREDI M: Physiological effects produced by botulinum toxin treatment of the upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain (1995) 118:801–807.
   Google Scholar
• GILADI N: The mechanism of action ofBotulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injection site. I Neurosci. (1997) 152:123–135.
   Google Scholar
• LEIS AA, DIMITRIJEVIC MR, DELAPASSE JS, SHARKEY PC: Modification of cervical dystonia by selective sensory stimulation. I Neurosci. (1992) 110:79–89.
   Google Scholar
• DEUSCHEL G, HEIREN F, KLEEDORFER B, WAGNER M, LUCKING CH, POEWE W: Clinical and polymyographic investigation of spasmodic torticollis. j Neura (1992) 239:9–15.
   PubMedGoogle Scholar
• ROSALES RL, ARIMURA K, TAKENAGA S, OSAME M: Extraffisal and intrafusal muscle effects in experimental botulinum toxin-a injection. Muscle & Nerve (1996) 19:488–496.
   PubMed Web of Science ®Google Scholar
• FILIPPI GM, ERRICO P, SANTARELLI R, BAGOLINI B, MANNI E: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol (1993) 113:400–404.
   PubMed Web of Science ®Google Scholar
• AOKI R: The development of BOTOX-itshistory and pharmacology. Pain Digest. (1998) 8:337–341.
   Google Scholar
• WEIGAND H, WELLHONER HH: The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Namara Schmiedebergs Arch. Pharmacol (1977) 298:235–238.
   PubMedGoogle Scholar
• ISKAWA H, MITSUI Y, YOSHITOMI T etal.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. biz j Ophthalmol (2000) 44:106–109.
   Google Scholar
• CUI M, AOKI KR: Botulinum toxin type a(BTX-a) reduces inflammatory pain in the rat formalin model. Cephalagia (2000) 20:414.
   Google Scholar
• ZUBER M, SEBALD M, BATHIEN N, DERECONDO J, RONDOT P: Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology (1993) 43:1715–1718.
   PubMed Web of Science ®Google Scholar
• BORODIC G, JOHNSON E, GOODNOUGH M, SCHANTZ E: Botulinum toxin therapy, immunologic resistance and problems with available material. Neurology (1996) 46:26–29.
   PubMed Web of Science ®Google Scholar
• DAUER WT, BURKE RE, GREENE P, FAHN S: Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 121:547–560.
   PubMed Web of Science ®Google Scholar